Business Wire

SEOUL-VIOSYS

3.3.2020 15:02:26 CET | Business Wire | Press release

Share
Seoul Viosys Sees Increased Demand for Its Violeds UV LED Technology for Sterilization Applications to Prevent the Spread of Coronavirus

Seoul Viosys , a leading global provider of UV LED technology and a subsidiary of Seoul Semiconductor, announced that customer inquiries for its violeds UV LED products, which are ideal for sterilizing bacteria, increased more than five times over the previous month, fueled by concerns over the continuing global spread of the coronavirus (COVID-19).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005072/en/

According to the Ultraviolet Germicidal Irradiation Handbook1 , one minute of UV-C light will sterilize more than 90% of the coronavirus. In addition, tests conducted by Chinese agencies on air appliances equipped with the violeds UV LED sterilization technology have demonstrated a 97% reduction in airborne virus particles.

With the growing concerns over the global spread of the coronavirus, numerous automotive companies in China are actively reviewing adoption of Seoul’s violeds UV LED technology in sterilization systems for vehicle interiors. In addition, violeds UV LED technology has been used by the US National Aeronautics and Space Administration (NASA) aboard the International Space Station (ISS) to provide a healthy, germ-free environment for astronauts.

Seoul’s violeds UV LED technology has been adopted by Maltani, the largest Korean lighting company, for sterilization lighting applications, and by RGF Environmental Group, the No.1 in-duct air treatment supplier in the U.S., for its [Halo-LED™] indoor air quality system launched in November of 2019, as shown in this YouTube video . In addition, violeds UV LEDs are used in water purifiers from SK Magic Co., Ltd. and Hyundai Rental Care Co., Ltd.

Until recently, many companies have been conservative in their adoption of UV LED technology because conventional UV LEDs typically had a short lifetime (10,000 hours) and high cost. However, Seoul Viosys recently improved the lifetime of their violeds UV LED to more than 50,000 hours, similar to visible LEDs used for general lighting applications, and increased production capacity to achieve cost competitiveness.

“Seoul Viosys is committed to developing technology that protects human health and creates a cleaner world, and we have long been involved in developing UV LEDs for innovative biomedical and agricultural applications,” said CEO Chung Hoon Lee, CEO of Seoul Semiconductor, which established Seoul Viosys 18 years ago to develop UV-LED technology in strategic partnerships with Japanese and U.S. companies. “Through innovation, sustained research and development, and manufacturing experience, we were able to improve the lifetime of UV LEDs up to 50,000 hours and significantly reduce product cost. We hope that Seoul’s violeds UV LED technology will help protect human health and create a cleaner world in the face of the current health situation.”

Seoul Viosys is currently run by its CEO Young joo Lee, who started the company in 2002.

1 Kowalski, W. 2009.Ultraviolet Germicidal Irradiation Handbook. Heidelberg, Germany: Springer-Verlag

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths range (200nm to 1600nm) including ultraviolet rays (UV), visible rays and infrared rays. It holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for strong sterilization and disinfection (UVC), skin regeneration (UVB), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add the advanced VCSEL technology which supports smartphone facial recognition and autonomous driving, and has started its mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Tech Sales Forecast to Reach $1.4 Trillion in 2026, Even as 56% of Consumers Delay Purchases, NIQ Finds1.9.2026 09:00:00 CEST | Press release

Global study finds price-sensitive shoppers will still pay more when products deliver clear, lasting benefits Global sales of consumer technology and durable goods are forecast to reach $1.4 trillion in 2026, up 5.1% year over year, even as 56% of consumers say they have delayed a technology purchase because of price or while waiting for a discount, according to new research from NIQ (NYSE: NIQ), the Official Global Insights Partner of IFA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901758503/en/ The era of automatic tech & durables upgrades is over. Released ahead of IFA 2026, which kicks off in Berlin on Sept. 4, 2026, NIQ today released its annual “State of Tech & Durables” report. Consumer Tech Trends 2027: How to Win When Every Purchase Must Be Justified examines how years of economic volatility have transformed technology purchasing behavior and what manufacturers and retailers must do to remain competitive. Key

Searchlight Capital Partners Announces Investment in Aderian Group1.9.2026 09:00:00 CEST | Press release

Partnership will support Aderian’s continued growth and expansion across the Nordic region Searchlight Capital Partners, L.P. ("Searchlight"), a leading global private investment firm, today announced an investment in Aderian Group ("Aderian" or the "Company"), a Nordic managed IT services provider serving more than 10,000 small and medium-sized enterprise ("SME") customers throughout Sweden and Norway. As part of the transaction, Aderian's management team will reinvest in the Company and remain meaningful shareholders alongside Searchlight, underscoring their continued commitment to Aderian's long-term growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901430715/en/ Aderian provides cloud, cybersecurity, AI and analytics, networking and modern workplace solutions. Since its founding in 2022, the Company has grown to approximately SEK 2.5 billion in revenue, with more than 850 employees and over 10,000 SME customers a

FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities1.9.2026 09:00:00 CEST | Press release

New license agreement enables an integrated workflow combining antibody labeling, human-relevant 3D testing and quantitative imaging for antibody-based therapeutics Debiopharm (Debiopharm Research & Manufacturing), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases and FluoSphera, a Swiss biotechnology company developing advanced in vitro platforms to improve the prediction of drug efficacy and safety, today announced a new license agreement for use of AbYlink™, Debiopharm’s proprietary antibody conjugation technology. The agreement enables FluoSphera to offer biotechnology and pharmaceutical companies an integrated workflow combining regio-selective antibody labeling, high-throughput testing in human-relevant three-dimensional models and quantitative imaging analysis. The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therape

Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release

Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro

Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release

Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye